156 related articles for article (PubMed ID: 27034145)
1. Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma.
Lee NH; Son MH; Choi YB; Yi E; Lee JW; Yoo KH; Sung KW; Koo HH
Cancer Res Treat; 2016 Oct; 48(4):1399-1407. PubMed ID: 27034145
[TBL] [Abstract][Full Text] [Related]
2. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of the detection of microcirculating tumor cells by a real-time RT-PCR assay of tyrosine hydroxylase in patients with advanced neuroblastoma.
Parareda A; Gallego S; Roma J; Llort A; Sábado C; Gros L; De Toledo JS
Oncol Rep; 2005 Oct; 14(4):1021-7. PubMed ID: 16142367
[TBL] [Abstract][Full Text] [Related]
4. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study.
Viprey VF; Gregory WM; Corrias MV; Tchirkov A; Swerts K; Vicha A; Dallorso S; Brock P; Luksch R; Valteau-Couanet D; Papadakis V; Laureys G; Pearson AD; Ladenstein R; Burchill SA
J Clin Oncol; 2014 Apr; 32(10):1074-83. PubMed ID: 24590653
[TBL] [Abstract][Full Text] [Related]
5. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
[TBL] [Abstract][Full Text] [Related]
6. Molecular detection of tyrosine hydroxylase in the peripheral blood of patients with neuroblastoma: useful at diagnosis but not predictive of subsequent relapse during off-therapy follow-up.
Lee ST; Ki CS; Sung KW; Kim HJ; Kim JW; Kim SH; Lee SH; Yoo KH; Koo HH; Kim JY; Cho EJ
Pediatr Hematol Oncol; 2011 Feb; 28(1):16-23. PubMed ID: 21083359
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease in peripheral blood stem cell harvests from high-risk neuroblastoma patients.
Avigad S; Feinberg-Gorenshtein G; Luria D; Jeison M; Stein J; Grunshpan A; Sverdlov Y; Ash S; Yaniv I
J Pediatr Hematol Oncol; 2009 Jan; 31(1):22-6. PubMed ID: 19125082
[TBL] [Abstract][Full Text] [Related]
8. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA.
Miyajima Y; Kato K; Numata S; Kudo K; Horibe K
Cancer; 1995 Jun; 75(11):2757-61. PubMed ID: 7743482
[TBL] [Abstract][Full Text] [Related]
9. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year.
Burchill SA; Lewis IJ; Abrams KR; Riley R; Imeson J; Pearson AD; Pinkerton R; Selby P
J Clin Oncol; 2001 Mar; 19(6):1795-801. PubMed ID: 11251011
[TBL] [Abstract][Full Text] [Related]
10. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma.
Burchill SA; Kinsey SE; Picton S; Roberts P; Pinkerton CR; Selby P; Lewis IJ
Med Pediatr Oncol; 2001 Jan; 36(1):213-9. PubMed ID: 11464888
[TBL] [Abstract][Full Text] [Related]
12. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
13. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction.
Kuroda T; Saeki M; Nakano M; Mizutani S
J Pediatr Surg; 1997 Jan; 32(1):69-72. PubMed ID: 9021573
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma.
Shono K; Tajiri T; Fujii Y; Suita S
J Pediatr Surg; 2000 Oct; 35(10):1415-20. PubMed ID: 11051140
[TBL] [Abstract][Full Text] [Related]
15. Detection procedures for neuroblastoma cells metastatic to blood and bone marrow: blinded comparison of chromogranin A heminested reverse transcription polymerase chain reaction to tyrosine hydroxylase nested reverse transcription polymerase chain reaction and to anti-GD2 immunocytology.
Pagani A; Macri L; Faulkner LB; Tintori V; Paoli A; Garaventa A; Bussolati G
Diagn Mol Pathol; 2002 Jun; 11(2):98-106. PubMed ID: 12045713
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two methods for evaluating bone marrow metastasis of neuroblastoma: Reverse transcription-polymerase chain reaction for tyrosine hydroxylase and magnetic resonance imaging.
Takemoto C; Nishiuchi R; Endo C; Oda M; Seino Y
Pediatr Int; 2004 Aug; 46(4):387-93. PubMed ID: 15310300
[TBL] [Abstract][Full Text] [Related]
17. Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA.
Miyajima Y; Horibe K; Fukuda M; Matsumoto K; Numata S; Mori H; Kato K
Cancer; 1996 Mar; 77(6):1214-9. PubMed ID: 8635146
[TBL] [Abstract][Full Text] [Related]
18. Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.
Yáñez Y; Grau E; Oltra S; Cañete A; Martínez F; Orellana C; Noguera R; Palanca S; Castel V
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1263-72. PubMed ID: 21706131
[TBL] [Abstract][Full Text] [Related]
19. Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma.
Tchirkov A; Paillard C; Halle P; Bernard F; Bordigoni P; Vago P; Deméocq F; Kanold J
J Hematother Stem Cell Res; 2003 Aug; 12(4):435-42. PubMed ID: 12965080
[TBL] [Abstract][Full Text] [Related]
20. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study.
Fukuda M; Miyajima Y; Miyashita Y; Horibe K
J Pediatr Hematol Oncol; 2001 Jan; 23(1):10-3. PubMed ID: 11196262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
